We are delighted to announce that we have invested in Oxford Brain Diagnostics (OBD), a University of Oxford spin-out, which has been launched to deliver a new method for diagnosing Alzheimer’s Disease from MRI scans.
The company is the result of an 8-year collaboration between Professor Steven Chance (neuroscience and pathology) and Professor Mark Jenkinson (brain imaging), and has resulted in the development of the Cortical Disarray Measurement (CDM), a novel approach that uses MRI scans to provide an index of the health of the cellular circuits in patients’ brains. CDM gives quantitative results to detect whether the patient is likely to develop dementia or not.
This platform technology will initially be applied to the diagnosis of Alzheimer’s disease, with the aim of enabling doctors to catch the condition years earlier than is possible with current diagnostic methods, and to help patients in all corners of the world.
Additionally the technology has the potential to be used to identify other brain conditions as the company grows and expands into new markets.
